Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $114.9 million.

  • Intellia Therapeutics' Cash from Financing Activities rose 3974.23% to $114.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.8 million, marking a year-over-year decrease of 5452.93%. This contributed to the annual value of $185.7 million for FY2024, which is 4252.82% up from last year.
  • Intellia Therapeutics' Cash from Financing Activities amounted to $114.9 million in Q3 2025, which was up 3974.23% from $14.7 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Cash from Financing Activities registered a high of $668.7 million during Q3 2021, and its lowest value of $2.2 million during Q1 2023.
  • For the 5-year period, Intellia Therapeutics' Cash from Financing Activities averaged around $98.1 million, with its median value being $32.6 million (2022).
  • Within the past 5 years, the most significant YoY rise in Intellia Therapeutics' Cash from Financing Activities was 11190670.02% (2021), while the steepest drop was 9902.6% (2021).
  • Over the past 5 years, Intellia Therapeutics' Cash from Financing Activities (Quarter) stood at $2.3 million in 2021, then surged by 22082.59% to $505.8 million in 2022, then tumbled by 78.95% to $106.5 million in 2023, then plummeted by 97.82% to $2.3 million in 2024, then skyrocketed by 4857.14% to $114.9 million in 2025.
  • Its last three reported values are $114.9 million in Q3 2025, $14.7 million for Q2 2025, and $2.3 million during Q4 2024.